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Previous evidence has suggested a relationship between male self-reported body size and
the risk of developing prostate cancer. In this UK-wide case-control study, we have explored
the possible association of prostate cancer risk with male self-reported body size. We also
investigated body shape as a surrogate marker for fat deposition around the body. As obe-
sity and excessive adiposity have been linked with increased risk for developing a number
of different cancers, further investigation of self-reported body size and shape and their
potential relationship with prostate cancer was considered to be appropriate.
Objective
The study objective was to investigate whether underlying associations exist between pros-
tate cancer risk and male self-reported body size and shape.
Methods
Data were collected from a large case-control study of men (1928 cases and 2043 controls)
using self-administered questionnaires. Data from self-reported pictograms of perceived
body size relating to three decades of life (20’s, 30’s and 40’s) were recorded and analysed,
including the pattern of change. The associations of self-identified body shape with prostate
cancer risk were also explored.
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Results
Self-reported body size for men in their 20’s, 30’s and 40’s did not appear to be associated
with prostate cancer risk. More than half of the subjects reported an increase in self-reported
body size throughout these three decades of life. Furthermore, no association was observed
between self-reported body size changes and prostate cancer risk. Using ‘symmetrical’
body shape as a reference group, subjects with an ‘apple’ shape showed a significant 27%
reduction in risk (Odds ratio = 0.73, 95% C.I. 0.57–0.92).
Conclusions
Change in self-reported body size throughout early to mid-adulthood in males is not a signifi-
cant risk factor for the development of prostate cancer. Body shape indicative of body fat
distribution suggested that an ‘apple’ body shape was protective and inversely associated
with prostate cancer risk when compared with ‘symmetrical’ shape. Further studies which
investigate prostate cancer risk and possible relationships with genetic factors known to
influence body shape may shed further light on any underlying associations.
Introduction
Prostate cancer is the most prevalent cancer in men [1]. It is also the third most common can-
cer-specific cause of death for men living in Europe [2, 3]. In 2016, it accounted for approxi-
mately one quarter of all cancers diagnosed in men within the UK [4]. Apart from the
established cancer risk factors, such as age, ethnicity and family history of prostate cancer in
first degree-relatives, other potential risk factors include height, obesity/high body mass index
(BMI) and levels of insulin-like growth factor-I [5–7].
Over the last few decades, obesity has increased by approximately 30% in European men [8,
9]. This has been linked to increased risk for developing several chronic diseases and cancers
[10]. Extensive studies have investigated the association of both obesity and body size with
prostate cancer risk. However, this relationship remains inconclusive [11–15]. Anthropo-
metrics that have been used to measure obesity and body adiposity include waist circumfer-
ence, waist-hip ratio and BMI [16]. The majority of epidemiologic studies investigating
prostate cancer risk have used BMI to evaluate obesity rather than body fat distribution [3].
Previous studies have suggested that high BMI is associated with increased risks for advanced,
aggressive and fatal prostate cancer [13, 15, 17–22]. In contrast, other studies have observed a
decreased risk of localised/indolent cancer [13, 15, 23–25]. A large meta-analysis consisting of
27 prospective studies of prostate cancer observed no or weak association between BMI and
total prostate cancer [26]. Similar findings have come from another systematic review examin-
ing the exposure in early adult life [27]. These conflicting results may in part be due to the fact
that BMI has been criticised for its inaccuracy in measuring obesity and its ability to differenti-
ate adipose and non-adipose tissues [28, 29]. This suggests that any association could be
dependent on particular disease subtypes and the age of exposure [6, 12, 13, 30].
Both body shape and body size have often been used to describe the characteristics of the
human body in health-related research. Defining obesity or adiposity through the use of clini-
cal judgement including a consideration of body size appearance provides an alternative
approach for determining the wider distribution of fat tissue over time.
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The issue of whether weight change during adulthood is more strongly associated with
prostate cancer than cross-sectional ‘current’ adiposity has not as yet been fully explored [31,
32]. Prostate cancer is characterised as being a slow developing disease. Thus the age that obe-
sity develops in early adult life may be an important factor within the aetiology of this cancer
[27, 33–35]. Moreover, early changes in prostate tissue have been seen in men during their
early adulthood, suggesting that body size over lifetime is important [33, 36]. Adult weight
change is a dynamic measure that could reflect imbalances in weight over time and it is
thought to be more accurate than a static measure of adiposity such as BMI [19, 37]. However,
these studies have reported inconsistent results [19, 31, 32]. Some studies found positive asso-
ciations between weight gain and prostate cancer [38] whereas others have found an inverse
association [39] or no association at all [14, 21]. In this study we specifically address the issues
of whether male self-reported body size and overall body shape and self-reported body size
and its change across three decades of life are associated with prostate cancer risk.
Methods
The ‘Prostate Cancer Study on Gene-Environment Interactions’ is a large scale case-control
study identifying and investigating potential risk factors for the development of prostate can-
cer in the UK. The study used a self-administered questionnaire and written informed consent
was obtained from each participant. Cases comprised adult men >36 years at diagnosis with
histologically confirmed prostate cancer. Male adult controls were selected from the same gen-
eral practices as cases. Eligible controls were men without history of prostate cancer and were
within an age range of ±5 years of cases. This study received ethical committee approval
MREC/99/4/013 (Trent Research Ethics Committee), 07/MRE04/29 (Nottinghamshire County
Teaching and Primary Care Trust).
Epidemiological data were collected for two time periods; the first between 1997–2004 and
the second between 2007–2009. In the second period, some additional questions were added
and other questions expanded within the questionnaire to provide more in-depth information,
including information on body shape. This was done following a preliminary analysis of data
collected from the first period. Data collection from the two time periods involved different
subjects and no repeated measurements were performed. Individuals did not contribute their
data more than once.
Data on education was based on the UK educational system and social class was based on
the UK occupational social class classification. Data on self-reported body size were avail-
able from both periods, but data on body shape were only available from the second period
of data collection. Self-reported body size at different ages was assessed using a pictogram
(Fig 1) with drawings of body silhouettes of nine different sizes ranging from 1 (very thin)
to 9 (severely obese) [40]. Subjects were asked to recall information relating to their self-
reported body size during their 20’s, 30’s and 40’s. Cases and controls were asked to rate
their perceived body size for the last 5 year period prior to diagnosis in case group and for
the last 5 years prior to receiving the questionnaire in control group. Participants were
excluded from the analysis if there were incomplete data (i.e. missing data for any decade).
This was done to ensure each participant has data to investigate self-reported body size
changes throughout decades. 1928 cases and 2043 controls were available for the analysis of
self-reported body size in the 20’s and 30’s. Six subjects were younger than 40 years of age at
the time data were collected; hence the number of cases and controls eligible for self-
reported body size analysis in the 40’s were 1924 and 2041 respectively. Ordinal scale data
(scale of 1 to 9) for self-reported body size at age 20’s, 30’s, 40’s were grouped into ‘thin’
(scale 1–3), ‘medium’ (scale 4–6) and ‘large’ (scale 7–9).
PLOS ONE Body size and shape with risk for prostate cancer: A UK case-control study
PLOS ONE | https://doi.org/10.1371/journal.pone.0238928 September 17, 2020 3 / 15
To explore the effect of self-reported body size increase during adulthood on prostate can-
cer risk, we restricted our analysis to include only subjects whose self-reported body size
remained as medium size from 20’s to 40’s as our reference group and subjects whose self-
reported body size was medium both in their 20s and 30s but increased to large in their 40’s as
our exposed group (Fig 1). There are 1057 cases and 1099 controls.
For body shape, participants were asked to select their body shape in four different forms
(apple, pear, oval and symmetrical) that best represented their body shape throughout their
life. Description of each body shape type was provided to aid subject’s understanding on its
meaning (‘Apple’ shape is where body fat is distributed mainly around the central abdominal
area; ‘Pear’ shape is where body fat is distributed mainly around the hip and thigh; ‘Oval’
shape is where body fat is distributed around the neck, chest, abdominal area and thigh; ‘Sym-
metrical’ shape is where the person has lean body with no fat). The numbers of subjects
included in this particular analysis were 1329 cases and 812 controls.
Statistical analysis
Logistic regression analysis was performed on the data using Stata version 15.0 [41]. Odds
ratios (ORs) and 95% confidence intervals (CIs) were estimated for total prostate cancer
risk. Forward stepwise logistic regression was performed on demographic factors to identify
potential confounders. The final multivariate logistic regression model included education,
ethnicity, study phase (I and II) and family history of prostate cancer in first-degree rela-
tives. Multivariable logistic regression was fitted with all confounders. Age was also
included as an a-priori variable in all regression models. For self-reported body size,
medium size was used as reference category and for pattern of change, no change from 20s
to 40s was used as reference group. In the multivariate model, self-reported body size at age
30’s and 40’s were adjusted further to self-reported body size at age 20’s to minimise the
effect of correlation between self-reported body size at age 20’s to age 30’s and 40’s. For
body shape, symmetrical shape was used as reference category. Estimated risks were
obtained from multivariate logistic regression models. A significant odds ratio is considered
when 95% C.I does not include 1.
Fig 1. Pictogram with silhouette drawings used for recalling self-reported body size at each decade 20s, 30s, and 40s (taken from
Stunkard et al, 1983).
https://doi.org/10.1371/journal.pone.0238928.g001
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Sensitivity analysis
We collected data on current BMI from both periods. A sensitivity analysis was performed to
explore if self-reported body size can be used as a proxy marker for BMI. We used the self-
reported body size and BMI reported during the last 5 years prior to completing the question-
naire only in the controls due to the fact that prostate cancer may have affected current BMI in
cases. Data were available in 766 controls. BMI as a continuous variable was normally distrib-
uted hence we applied Analysis of Variance (ANOVA) to explore the differences among group
means. A finding was deemed to be statistically significant when the P-value was less than
0.05.
Study power
As they are no previous studies on body shape and prostate cancer, we computed our study
power based on exposure in our study. Our study of 1329 case and 812 controls with a proba-
bility of exposure (apple body shape) among controls of 0.62, had a 95% study power to detect
odds ratios for disease of 0.72 or 1.41 [42].
Results
The overall study response rates after initial consent to complete the questionnaire were 85.0%
for cases and 74.4% for controls. Table 1 shows the study population characteristics. The
median age for both case and control subjects was 60 and 59 years respectively. The vast major-
ity of study subjects described themselves as white (98%).
Table 2 summarises the number of subjects and their self-reported body size at each of the
three decades of their life. The majority of participants was medium across all three decades in
both case and control groups.
Table 3 summarises odds ratios of self-reported body size changes and prostate cancer risk.
Both cases and controls have similar percentage of self-reported body size change from
medium to large in their 40’s (~30%). The result suggests that there is no association with can-
cer risk for subjects whose self-reported body size increased from medium to large as com-
pared to subjects with medium self-reported body size throughout their adulthood.
Table 4 presents estimated risks of different self-reported body shape and prostate cancer
risk. Compared to symmetrical shape, subjects with an apple shape were at 27% risk reduction
(OR in the fully adjusted model = 0.73 with 95% CI 0.57–0.92). Both pear and oval shape did
not show any association with prostate cancer risk in the fully adjusted model of 1.44 (95% CI
0.77–2.69) and 0.82 (95% CI 0.59–1.13) respectively. Although, the association is not signifi-
cant, but the direction of effect suggested that adipose tissue distributed around the hip and
thigh (pear) is at higher risk, while abdominal fat distribution (apple, and oval) is at lower risk.
Results from sensitivity analysis (only in the control group) using ANOVA test is presented
in Table 5. The significant p-value suggested that mean BMI in each group is a statistically sig-
nificant difference. BMI increases with increased self-reported body size indicative of a good
proxy between BMI and body size.
Discussion
Three key areas potentially relating to increased risk for prostate cancer were explored in this
study; self-reported body size at early and mid-adulthood, self-reported body size changes over
decades in life, and self-identified body shape.
Self-reported body size (thin, medium, and large) ranging across three decades (20’s, 30’s
and 40’s) was explored and analysis suggested no associations between the self-reported body
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size at each stage of life among cases and control group and risk of prostate cancer however
our analysis could be underpowered given the relatively small numbers in the 20’s/large and
40’s/thin category. Furthermore, the analysis suggested that 55% of both case and control sub-
jects had a history of changes in self-reported body size. Our ad hoc analysis also showed that
the magnitude of changes of self-reported body size from age 20’s to 40’s varies between indi-
viduals (result not shown here). Approximately 53% of those self-reported body size changes
were of increase in size (either for both periods-20s to 30s and 30s to 40s or at 20s to 30s and
no change in 30s to 40s). The possible explanation for increase in body size is because of
decreased metabolic rate with ageing and accumulation over the years of unburned calorie
intakes. Environmental factors such as eating high-fat foods or lack of exercise, as well as Sed-
entary Lifestyle Syndrome (SeDS) could also be accountable for increasing in body size [43].
Table 1. Demographic and social characteristics of participants in the prostate cancer study on gene-environment interactions.
Characteristics Cases (n = 1,928) Controls (n = 2,043) OR of prostate cancer (95% CI)
Median Median
Age (years) 60 (range 36–84) 59 (range 36–76)
n (%) n (%)
Marital Status
Married or partnership 1,585 (82.2%) 1,691 (82.8%) -Ref-
Divorced, separated or widowed 227 (11.8%) 260 (12.7%) 0.93 0.77–1.13
Single 89 (4.6%) 68 (3.3%) 1.39 1.01–1.93
Missing 27 (1.4%) 24 (1.2%)
Education
No qualifications 433 (22.5%) 558 (27.31%) -Ref-
GCSE, O levels or equivalent 357(18.5%) 342 (16.74%) 1.35 1.11–1.64
A levels, higher or equivalent 132 (7.0%) 148 (7.24%) 1.16 0.89–1.51
Higher or professional qualification e.g. degree, HND 716 (37.0%) 742 (36.32%) 1.25 1.06–1.47
Others 252 (13.0%) 229 (11.21%) 1.42 1.14–1.76
Missing 38 (2.0%) 24 (1.17%)
Ethnicity
White 1,832 (95.0%) 2,000 (97.9%) -Ref-
Black 29 (1.5%) 4 (0.2%) 8.1 2.84–23.12
Asian 13 (0.7%) 7 (0.34%) 1.99 0.79–5.02
Other 26 (1.4%) 13 (0.64%) 2.19 1.12–4.29
Missing 28 (1.4%) 19 (0.93%)
Social class
I 236 (12.2%) 224 (11%) -Ref-
II 797 (41.3%) 851 (41.7%) 0.89 0.72–1.10
IIIN 193 (10.0%) 208 (10.2%) 0.88 0.67–1.15
IIIM 499 (26.0%) 528 (25.8%) 0.90 0.73–1.13
IV 108 (5.6%) 111 (5.4%) 0.93 0.67–1.28
V 18 (0.9%) 31 (1.5%) 0.56 0.30–1.02
Missing 77 (4.0%) 90 (4.4%)
Family history of prostate cancer
No 1,312 (68.0%) 1,880 (92.0%) -Ref-
Yes 533 (27.7%) 100 (4.9%) 7.61 6.08–9.54
Missing 83 (4.3%) 63 (3.1%)
�Unadjusted OR. The rest of ORs were adjusted for age.
https://doi.org/10.1371/journal.pone.0238928.t001
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These possible explanations are compatible with the considerable social and life style changes
that have occurred across the UK over the last 30 years.
The findings of previous studies regarding obesity at early and mid-adulthood are inconclu-
sive. Our results are consistent with the majority of epidemiologic studies that found no associ-
ations between self-reported body size in early as well as middle to late adulthood and prostate
cancer risk [14, 21, 27, 39, 44, 45]. More recently, a research group (the Prostate Cancer Asso-
ciation Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)
consortium) investigated potential causal relationship between BMI and prostate cancer using
genetic approaches to analyse 20848 cases and 20214 controls. This also failed to identify any
significant associations between BMI and prostate cancer [46]. Our study also did not find any
association between changes in self-reported body size over decades (increase in self-reported
body size to large in the 40’s compared to remains medium throughout) and prostate cancer
risk. This finding is inconsistent with several other studies where some relationships with pros-
tate cancer were observed [14, 19, 24, 38, 47, 48]. This inconsistency could be due to the differ-
ent measurements used by these studies which used actual weight, BMI or waist circumference
to indicate the change in body size. In contrast, in our study we used pictograms as a surrogate
for body size. We also performed analyses of BMI and perceived body size within different
social class and education in the control group and the results suggested a very similar correla-
tion to that seen in the main sensitivity analysis. Furthermore, the other studies used multiple
parameters to measure body size when investigating the relationship of change of body size
with prostate cancer. As such there was therefore a higher possibility of obtaining statistical
Table 2. Self-reported body sizes at each decade among cases and controls.
Body size at 20’s Cases Controls OR of prostate cancera OR of prostate cancerb
Medium 1,159 (60.1%) 1,208 (59.1%) -Ref- -Ref-
Thin 690 (35.8%) 736 (36.0%) 0.97 (0.85–1.11) 1.10 (0.95–1.28)
Large 79 (4.1%) 99 (4.9%) 0.84 (0.62–1.14) 0.95 (0.66–1.35)
Body size at 30’s �
Medium 1,497 (77.7%) 1,573 (77.0%) -Ref- -Ref-
Thin 255 (13.2%) 273 (13.4%) 0.97 (0.80–1.17) 0.97 (0.77–1.22)
Large 176 (9.1%) 197 (9.6%) 0.96 (0.77–1.19) 1.00 (0.77–1.30)
Body size at 40’s �
Medium 1,291 (67.1%) 1310 (64.2%) -Ref- -Ref-
Thin 70 (3.6%) 91 (4.5%) 0.77 (0.56–1.06) 0.85 (0.58–1.23)
Large 563 (29.3%) 640 (31.4%) 0.91 (0.80–1.05) 1.00 (0.85–1.75)
a Age-adjusted regression model
b Multivariate adjusted regression model for age, education, ethnicity, study phase and family history of prostate cancer
�Body size at 30’s and 40’s adjusted further to body size at 20’s in the multivariate model
https://doi.org/10.1371/journal.pone.0238928.t002
Table 3. Estimated risk of self-reported body size changes and prostate cancer risk.
Group Cases Controls OR of prostate cancera (95%CI) OR of prostate cancerb (95%CI)
Body size remains thin or medium throughout adulthood 738 758 -Ref- -Ref-
Body size increase to large in their 40s 319 341 0.97 (0.81–1.17) 1.07 (0.87–1.33)
Total 1,057 1,099
a Age-adjusted regression model
b Multivariate adjusted regression model for age, education, ethnicity, study phase and family history of prostate cancer
https://doi.org/10.1371/journal.pone.0238928.t003
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significant findings in at least one of the measurement parameters. The other limitation is that
our data is only limited to middle age (40s) hence this may not be the period in life that obesity
associates with prostate cancer. Our results which failed to show association are in keeping
with the majority of other studies that investigated the association between weight change and
prostate cancer risk [12, 31, 32, 39, 44, 45, 49–53].
A limitation of using pictorial illustration is its inability to make an actual measurement of
changes in body size in comparison with using other parameters such as weight, waist circum-
ference or waist-hip ratio, BMI or body fat mass. As such, pictorial assessment of self-reported
body size is relative, but it may be better for showing body size change over long time win-
dows. Pictograms are considered to be a valid and useful method to assess self-reported body
size and differentiate thin and obese individuals [54]. The Stunkard Figure Rating (SFR) scale
of body size [40] tool has been validated for historic recall of body size and was used in a large
European population to explore correlation between self-reported body silhouettes and the
previously measured (9–23 years) BMI [55]. The authors reported an area under the curve of
0.92 (95% CI 0.87, 0.97) in women and 0.85 (95% CI 0.75, 0.95) in men for identifying obesity
at age 30 using body silhouettes vs previously measured BMI at age 30 (±2y). The findings
were also similar for previously self-reported BMI, 0.92 (95% CI 0.88, 0.95) and 0.90 (95% CI
0.85, 0.96) in women and men respectively. Another study assessing adolescent body size
found that Stunkard’s method was a useful indicator in absence of measured BMI [56]. It is
also has been reported that recalled body size using pictograms showed a strong correlation
with measured weight at age 20–40 years with a correlation ranging from 0.51 to 0.95 [57–59].
Our result from sensitivity analysis in controls suggested that pictogram can potentially be
used for recall of body size. Nevertheless, personal perception of body size of each individual
could introduce bias such as classification bias.
Table 4. Odd ratios of self-reported body shape on prostate cancer risk.
Self-reported body shape Case Control OR of prostate cancera (95%CI) OR of prostate cancerb (95%CI)
Symmetric 349 173 -Ref- -Ref-
Apple 735 504 0.67 (0.53–0.83) 0.73 (0.57–0.93)
Pear 51 17 1.57 (0.87–2.85) 1.47 (0.78–2.76)
Oval 194 118 0.76 (0.56–1.02) 0.82 (0.59–1.14)
a Age-adjusted regression model
b Multivariate adjusted regression model for age, education, ethnicity, and family history of prostate cancer
https://doi.org/10.1371/journal.pone.0238928.t004
Table 5. BMI and self-reported body size in control group�.
Body size Number Mean Std. Dev.
2 6 20.23 1.69
3 17 21.78 2.07
4 48 22.97 1.67
5 103 24.02 2.39
6 168 25.44 2.07
7 254 27.46 3.13
8 135 30.18 3.56
9 35 34.14 4.49
�ANOVA F-test P-value <0.05
https://doi.org/10.1371/journal.pone.0238928.t005
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Cohort studies often obtain more valuable data by longitudinally measuring and recording
body weight, waist/hip circumference and body fat mass. Implementing this approach was not
possible in our study. Some medical conditions, such as hypo or hyperthyroidism, can affect
body size. However the prevalence of both these conditions in the UK is low (1–2% for both
conditions) [60] and therefore unlikely to affect our results. As our study is subject to classifi-
cation bias, we opted to broadly group body size into three groups to minimise any bias; i.e.
thin, medium and large.
We are not aware of any published research on the prevalence of different types of body fat
distribution in the population. However waist and chest circumference measurement in males
are the closest for describing whether a person shape can be described as ‘apple’ or be a proxy
of central adiposity [61]. Male shape seems to remain highly stable throughout adult life, there-
fore it is reasonable to assume that characteristic of body fat distribution also remains the
same.
Our results suggest that subjects with an ‘apple’ shape indicative of body fat distributed
mainly around the abdomen, were at reduced risk with both adjusted and unadjusted when
compared to those with a ‘symmetrical’ shape. However, the ‘pear’ and ‘oval’ body shapes did
not show any statistically significant associations. A recent cohort study reported by Barberio
involving 26607 subjects, found central body adiposity to be more associated with cancer risk
than overall body size [62]. Although the cohort examined the association with cancer in gen-
eral, our results of self-identify body shape indicative of the distribution of fat tissue around
the body suggested similar findings.
In contrast to ‘apple’ or ‘pear’ body shape, hip circumference indicates increased amounts
of subcutaneous fat. Thus ‘apple’ body shape in actual measurement would predict wider waist
circumference (WC) or higher waist to hip ratio (WHR). Studies using actual measurement
have shown increased risk in advanced or high-grade prostate cancer in such individuals [3,
16, 30, 63, 64].
Several possible explanations have been proposed regarding association between central
adiposity and prostate cancer. Adiposity can potentially impact through multiple hormonal
pathways. Adiposity has been associated with higher levels of insulin, insulin like growth factor
I, leptin, and inflammatory cytokines. It has also been linked with lower levels of adiponectin
and free testosterone. All of these may impact on prostate cancer development and progression
[20, 65–72]. Moreover, some studies showed that adiposity lowered the risk of non-aggressive
prostate cancer while at the same time increased the risk for aggressive and high-grade prostate
cancer [3, 5, 8, 14, 16, 20, 21, 24, 25, 30, 33, 73]. However other studies have observed weak or
no association with prostate cancer and disease subtypes [12, 74–76].
As yet no other study reported in the literature has used body shape as proxy measure of
body fat distribution to investigate possible associations with prostate cancer. Our findings
suggest that abdominal fat deposition (apple body shape) maybe protective of prostate cancer.
Diabetes is known to be linked with obesity and also shows an inverse association with the
risk of prostate cancer [77–79]. One of the limitations is that we collected data on diabetes
only in period 2 with no details of diabetes type. However, we carried out logistic regression
analysis incorporating diabetes in our model, our results remain the same. Likewise, we also
investigated the association of both smoking and physical activity with prostate cancer and
there were no associations. Therefore, we did not include these variables in our final model.
In this study, we used self-reported descriptions within the questionnaire to capture the
types of body fat distribution. This approach is likely to be less accurate than using 3-dimen-
sional body shape scanning as used in UK National Sizing survey [61] conducted in 2001 to
2002. This cross-sectional study of 9617 adults found that male body shape remained highly
stable throughout adulthood. Such quantitative approaches may reveal further insights into
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